Abstract | INTRODUCTION: METHODS: BxPC-3, PANC-1, and MIA PaCa-2 human pancreatic cancer cell lines were treated with gemcitabine and/or DMAPT. Effects on the NF-κB pathway were determined by electrophoretic mobility shift assay, ELISA, or Western blot. Proliferation and apoptosis were measured by cell counts and ELISA, respectively. The effect of gemcitabine in vivo was determined using a MIA PaCa-2 heterotopic xenograft model. RESULTS:
Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. DMAPT prevented the gemcitabine-induced activation of NF-κB. The combination of DMAPT/ gemcitabine inhibited pancreatic cancer cell growth more than either agent alone. Gemcitabine also induced intratumoral NF-κB activity in vivo. CONCLUSIONS:
|
Authors | Bryan K Holcomb, Michele T Yip-Schneider, Joshua A Waters, Joal D Beane, Peter A Crooks, C Max Schmidt |
Journal | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
(J Gastrointest Surg)
Vol. 16
Issue 7
Pg. 1333-40
(Jul 2012)
ISSN: 1873-4626 [Electronic] United States |
PMID | 22618517
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antimetabolites, Antineoplastic
- LC-1 compound
- NF-kappa B
- Sesquiterpenes
- Deoxycytidine
- Gemcitabine
|
Topics |
- Animals
- Antimetabolites, Antineoplastic
(pharmacology, therapeutic use)
- Apoptosis
(drug effects)
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Deoxycytidine
(analogs & derivatives, pharmacology, therapeutic use)
- Drug Resistance, Neoplasm
(drug effects, physiology)
- Electrophoretic Mobility Shift Assay
- Enzyme-Linked Immunosorbent Assay
- Humans
- Mice
- Mice, Nude
- NF-kappa B
(antagonists & inhibitors, metabolism)
- Pancreatic Neoplasms
(drug therapy, pathology)
- Sesquiterpenes
(pharmacology)
- Gemcitabine
|